Prospective Multicenter Cohort Study for the Development and Evaluation of Risk Stratification Tools for Lung Cancers and Their Postoperative Recurrences Using Multimodal Clinical, Radiological, Tissue and Longitudinal Biological Phenotyping Among People at Risk of Lung Cancer

NCT ID: NCT07042867

Last Updated: 2025-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-15

Study Completion Date

2028-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Interventional study with minimal risks and constraints, involving annual assessment of the prevalence and incidence of lung cancer using low-dose contrast-free thoracic CT scans, immunological, inflammatory, metabolic, blood nucleic acid and digestive microbiota profiles; systematic proposal of smoking cessation for active smokers, or assistance in maintaining cessation This is a prospective validation study of risk stratification tools still under development.

The results of this study will be used to design medical devices (software integrating risk stratification tools), which will then be evaluated as part of subsequent Clinical Investigations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer (Diagnosis)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: patients with a nodule or lung mass identified on CT scan, with no indication of an immedi

patients with a nodule or lung mass identified on CT scan, with no indication of an immediate diagnostic workup

Group Type OTHER

biobanking

Intervention Type BIOLOGICAL

blood draw at each time point

low dose scan

Intervention Type RADIATION

low dose lung scan will be performed at each timepoint

Group B: cohort of patients with a nodule or lung mass identified on CT with an indication for biops

cohort of patients with a nodule or lung mass identified on CT with an indication for biopsy or excision surgery

Group Type OTHER

biobanking

Intervention Type BIOLOGICAL

blood draw at each time point

low dose scan

Intervention Type RADIATION

low dose lung scan will be performed at each timepoint

Group C: Individuals with at least one risk factor for lung cancer and no prior lung imaging, but no

Individuals with at least one risk factor for lung cancer and no prior lung imaging, but not eligible for lung cancer screening according to INCa criteria.

Group Type OTHER

biobanking

Intervention Type BIOLOGICAL

blood draw at each time point

low dose scan

Intervention Type RADIATION

low dose lung scan will be performed at each timepoint

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

biobanking

blood draw at each time point

Intervention Type BIOLOGICAL

low dose scan

low dose lung scan will be performed at each timepoint

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group A:

CI 1- Age \> 18 years AND CI2a- Person eligible for screening with a nodule or lung mass with no indication of reassessment by CT scan before the next round of screening, as recommended by the multidisciplinary consultation meeting OR CI2b- Person not eligible for screening with a nodule or lung mass with an indication for reassessment by CT scan without immediate diagnostic workup (PET scan, biopsy, surgery) as determined by the multidisciplinary consultation meeting.

Group B CI1- Age \> 18 years AND CI2- Indication for biopsy or surgical excision for diagnostic and therapeutic purposes proposed in a multidisciplinary consultation meeting.

Group C CI1a- Age 40 - 75 and daily smoking for at least 20 years initiated before age 15 OR CI1b- Age 50 - 75 and passive smoking for at least 20 years in a closed environment (family or workplace) OR CI1c- Age 50 - 75 and smoking 10 cig/d for 30 years or 15 cig/d for 25 years or 20 pack-years with no withdrawal period OR

CI1d- Age 50 - 75 and daily smoking for at least 10 years combined with at least one other lung cancer risk factor from among :

* Self-reported daily passive smoking for \> 10 years (smokers at home or in enclosed environments)
* Self-reported exposure to a lung carcinogen: Radon, coal smoke, soot, diesel, nickel, beryllium, arsenic, cadmium, asbestos
* 1st-degree family history of lung cancer
* Personal history of tobacco-related disease, including atheromatous cardiovascular disease, COPD or emphysema, cancer not monitored by chest imaging
* weekly use of cannabis (joints) for 10 years

All Groups:

* Have signed an informed consent form
* Affiliated with or benefiting from a social security scheme
* Male or female

Exclusion Criteria

Goups A and B Contraindication to lung biopsy or thoracic surgery for diagnostic or therapeutic purposes

Group C Eligible for lung cancer screening according to INCa\* criteria

* Previous cancer \< 5 years (except carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin, non-invasive urothelial carcinoma treated for curative purposes without CT lung surveillance, prostate cancer with undiagnosable PSA)
* Symptoms of lung cancer (involuntary weight loss \> 10% of usual weight in 1 year, hemoptysis)
* Known history of pulmonary nodule requiring specialized follow-up
* History of pulmonary fibrosis or pulmonary hypertension
* Active pulmonary parenchymal infection
* Severe cardiac or respiratory insufficiency (rest dyspnea)
* Performance status (WHO) 2, 3 or 4

All Groups

* patient privé de liberté
* patient sous tutelle ou curatelle
* femmes enceintes ou allaitantes
* patient dans l'incapacité d'effectuer le suivi de 30 mois
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Boulate, Professor of Medicine

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique Hopitaux De Marseille

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

David Boulate, Professor

Role: CONTACT

+33 491966018

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-A02828-39

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Early Detection of Lung Cancer
NCT03181256 ACTIVE_NOT_RECRUITING
Nashville Early Diagnosis Lung Cancer Project
NCT01475500 ACTIVE_NOT_RECRUITING